Okay, I can understand your confusion here.
The idea is that it's only national R and D inside the country versus all the sales of all the companies around the world inside that country as well. So basically in Canada we spent something like $18 billion to buy patented pharmaceutical products in 2011, but what we got in terms of R and D investment in the pharmaceutical sector in the country was $960 million.
So the comparison is based on all investment nationally, but also all the sales of all pharmaceutical companies around the world in that specific country as well. This is what is used here as the main comparator for R and D intensity in different countries.